GW Pharmaceuticals to Present at Upcoming Investor Conferences
November 22 2019 - 7:00AM
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the science, development, and commercialization of
cannabinoid prescription medicines, today announced that Justin
Gover, GW’s Chief Executive Officer, will present at two upcoming
conferences:
- Evercore ISI 2nd Annual HealthCONx Conference, on Wednesday,
December 4th, 2019 at 10:15 a.m. EST
- Piper Jaffray 31st Annual Healthcare Conference on Thursday,
December 5th, 2019 at 8:30 a.m. EST
A live audio webcast of the presentations will
be available through GW’s corporate website at www.gwpharm.com on
the Investors section under Events & Presentations. A replay
will be available for each soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW’s lead
product, EPIDIOLEX (cannabidiol) oral solution is commercialized in
the U.S. by its U.S. subsidiary Greenwich Biosciences for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. This
product has received approval in Europe under the tradename
EPIDYOLEX and is initially being commercialized in the 5 EU major
markets. The Company continues to evaluate EPIDIOLEX in additional
rare conditions including Tuberous Sclerosis Complex (TSC) and Rett
syndrome. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
Company is now advancing a late stage program in order to seek FDA
approval. The Company has a deep pipeline of additional cannabinoid
product candidates which includes compounds in Phase 1 and 2 trials
for epilepsy, autism, glioblastoma, and schizophrenia. For further
information, please visit
www.gwpharm.com.Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024